Platinum Investment Management Ltd. lifted its stake in shares of Orchard Therapeutics plc (NASDAQ:ORTX – Free Report) by 108.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 248,462 shares of the company’s stock after purchasing an additional 129,334 shares during the quarter. Platinum Investment Management Ltd. owned 1.35% of Orchard Therapeutics worth $1,294,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jane Street Group LLC grew its holdings in shares of Orchard Therapeutics by 64.6% during the 4th quarter. Jane Street Group LLC now owns 75,643 shares of the company’s stock valued at $28,000 after purchasing an additional 29,690 shares during the last quarter. Bank of America Corp DE boosted its position in Orchard Therapeutics by 130.8% during the 1st quarter. Bank of America Corp DE now owns 95,749 shares of the company’s stock worth $68,000 after buying an additional 54,270 shares during the period. Millennium Management LLC acquired a new stake in Orchard Therapeutics during the 2nd quarter worth approximately $106,000. Mariner LLC acquired a new stake in Orchard Therapeutics during the 4th quarter worth approximately $234,000. Finally, BlackRock Inc. boosted its position in Orchard Therapeutics by 19.9% during the 1st quarter. BlackRock Inc. now owns 749,990 shares of the company’s stock worth $534,000 after buying an additional 124,478 shares during the period. 29.90% of the stock is owned by institutional investors.
Analysts Set New Price Targets
ORTX has been the topic of several recent research reports. Cantor Fitzgerald downgraded shares of Orchard Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Friday, October 6th. Stifel Nicolaus downgraded shares of Orchard Therapeutics from a “buy” rating to a “hold” rating and set a $16.00 target price on the stock. in a research report on Thursday, October 5th. Finally, Oppenheimer reiterated an “outperform” rating and set a $34.00 target price on shares of Orchard Therapeutics in a research report on Wednesday, August 9th.
Orchard Therapeutics Stock Up 1.2 %
Shares of Orchard Therapeutics stock traded up $0.20 during trading on Tuesday, reaching $16.25. 82,949 shares of the company traded hands, compared to its average volume of 123,888. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.12 and a quick ratio of 3.03. Orchard Therapeutics plc has a 1-year low of $3.60 and a 1-year high of $16.29. The company has a 50 day moving average price of $12.88 and a 200-day moving average price of $7.85. The firm has a market capitalization of $369.25 million, a PE ratio of -17.07 and a beta of 0.50.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency.
- Five stocks we like better than Orchard Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Wynn Resorts has an ace up its sleeve
- How to Invest in Blockchain Stocks Step by Step
- Zoom Video Communications: A tech phoenix ready to rise
- Consumer Staples Stocks, Explained
- The only two airline stocks worth buying: One is a Goldman pick
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.